Advanced search
Publication Cover
Current Medical Research and Opinion Volume 28, 2012 - Issue 1
Submit an article Journal homepage
646
Views
18
CrossRef citations to date
0
Altmetric
Psychiatry: Original Article

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

Carol R. ReedFormer employee of Dogwood Pharmaceuticals, a subsidiary of Forest Laboratories, Inc. New Haven, CT, USACorrespondence[email protected]
,
Daniel K. KajdaszDogwood Pharmaceuticals, a subsidiary of Forest Laboratories, Inc. New Haven, CT, USA
,
Heidi WhalenDogwood Pharmaceuticals, a subsidiary of Forest Laboratories, Inc. New Haven, CT, USA
,
Maria C. AthanasiouAthanasiou Consulting, LLC Fond du Lac, WI, USA
,
Susan GallipoliFormer employee of Dogwood Pharmaceuticals, a subsidiary of Forest Laboratories, Inc. New Haven, CT, USA
&
Michael E. ThaseUniversity of Pennsylvania School of Medicine Philadelphia, PA, USA
Pages 27-39 | Accepted 27 Sep 2011, Published online: 23 Nov 2011

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

David J Hellerstein & Joseph Flaxer. (2015) Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evidence 10, pages 49-62.
Read now
William James Deardorff & George T Grossberg. (2014) A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opinion on Pharmacotherapy 15:17, pages 2525-2542.
Read now
Jennifer A Reinhold, Laura A Mandos, Falk W. Lohoff & Karl Rickels. (2012) Evidence for the use of vilazodone in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 13:15, pages 2215-2224.
Read now

Articles from other publishers (15)

Susan Kornstein, Cheng-Tao Chang, Carl P. Gommoll & John Edwards. (2018) Vilazodone efficacy in subgroups of patients with major depressive disorder. International Clinical Psychopharmacology 33:4, pages 217-223.
Crossref
Yu-hua Ran, Xiao-xu Hu, Yu-lu Wang, Nan Zhao, Li-ming Zhang, Hua-xia Liu & Yun-feng Li. (2017) YL-0919, a dual 5-HT1A partial agonist and SSRI, produces antidepressant- and anxiolytic-like effects in rats subjected to chronic unpredictable stress. Acta Pharmacologica Sinica 39:1, pages 12-23.
Crossref
Xiu-Rong Hu, Jia-Li Ye & Jian-Ming Gu. (2016) Crystal structure of vilazodone hydrochloride methanol monosolvate. Acta Crystallographica Section E Crystallographic Communications 72:12, pages 1783-1785.
Crossref
Priya Bawa, Priyamvada Pradeep, Pradeep Kumar, Yahya E. Choonara, Girish Modi & Viness Pillay. (2016) Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. Drug Discovery Today 21:12, pages 1886-1914.
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs 111 143 .
William James Deardorff & George T. Grossberg. (2015) The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Current Geriatrics Reports 4:4, pages 301-311.
Crossref
Stuart A. Montgomery, Carl P. Gommoll, Changzheng Chen & William M. Greenberg. (2014) Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectrums 20:2, pages 148-156.
Crossref
Katherine Semenkovich, Miriam E. Brown, Dragan M. Svrakic & Patrick J. Lustman. (2015) Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment. Drugs 75:6, pages 577-587.
Crossref
Mark J. Millan. (2013) On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. The International Journal of Neuropsychopharmacology 17:07, pages 1009-1037.
Crossref
Jeremy D. Coplan, Srinath Gopinath, Chadi G. Abdallah & Benjamin R. Berry. (2014) A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy. Frontiers in Behavioral Neuroscience 8.
Crossref
Glen I. SpielmansIrving Kirsch. (2014) Drug Approval and Drug Effectiveness. Annual Review of Clinical Psychology 10:1, pages 741-766.
Crossref
Lili Xu, Shanglin Zhou, Kunqian Yu, Bo Gao, Hualiang Jiang, Xuechu Zhen & Wei Fu. (2013) Molecular Modeling of the 3D Structure of 5-HT 1A R: Discovery of Novel 5-HT 1A R Agonists via Dynamic Pharmacophore-Based Virtual Screening . Journal of Chemical Information and Modeling 53:12, pages 3202-3211.
Crossref
Hong-xia Chen, Zeng-liang Jin, Li-ming Zhang, Rui Xue, Xiao-dan Xu, Nan Zhao, Zhi-kun Qiu, Xian-wang Wang, You-zhi Zhang, Ri-fang Yang & Yun-feng Li. (2013) Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist. PLoS ONE 8:12, pages e83271.
Crossref
Charles R. AshbyJr.Jr., John H. Kehne, Gerd D. Bartoszyk, Matthew J. Renda, Maria Athanasiou, Kerri A. Pierz & Christoph A. Seyfried. (2013) Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. European Journal of Pharmacology 714:1-3, pages 359-365.
Crossref
Joanne Bronson, Murali Dhar, William Ewing & Nils Lonberg. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47 499 569 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.